Saturday 10 October 2026 Export all AZN data to Excel Powerpack

AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.

159.20 0.42 +0.26%
Market cap
$246.3B
P/E
23.6×
Fwd P/E
23.4×
Dividend yield
2.02%
F-score
9/9
Altman Z
6.26
Beneish M
−2.51
Dividend safety
54/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
21.95% 23.47% 22.83% 21.66%

+8 more TTM periods

Piotroski F-Score
8 9 8 7
ROA
9.15% 9.43% 9.38% 8.57%
ROIC
11.67% 12.48% 12.15% 11.65%
Return on Tangible Assets
104.18% 102.21% 92.38% 117.93%
Average Days of Receivables
95.10 91.58 101.50 95.15
Free Cash Flow per Share
4.04 5.13 2.84 6.25
Free Cash Flow
6,265.00 7,939.00 8,819.00 9,691.00
Other line items

Show all line items

Columns are period end dates